FDA Panel Review Of J&J Cypher Stent Will Weigh SIRIUS Late Loss Data

Johnson & Johnson/Cordis' upcoming presentation before an FDA advisory panel on the Cypher drug-eluting stent will highlight a 67% reduction of target vessel failure (TVF) at nine months compared with bare stents